Repeal Medicaid Generics Penalty | Association for Accessible Medicines
CPI - Medicaid Generics Tax
The Medicaid Generics Penalty is a mistake.
#RepealMedicaidPenalty

Repeal Medicaid Generics Penalty

Although it was sold as a harmless extension of a policy that applies to brand-name pharmaceuticals, the penalty ignores the fundamental differences between how brand-name and generic medicines are priced. Unless it is repealed, it could destabilize the robust market for generic drugs and impede patient access to affordable, lifesaving drugs.

What is the Medicaid Generics Penalty?

The Medicaid Generics Penalty is paid by generic drug manufacturers when the Average Manufacturer Price (AMP) of a generic drug sold to Medicaid rises faster than the Consumer Price Index (CPI) over a three-month period. While this is ostensibly designed to prevent manufacturers from raising prices, the penalty is often triggered by forces beyond the manufacturer’s control and not by price increases.

Why should patients care?

The measure could force generic manufacturers out of the marketplace if they must sell their products to Medicaid at a loss. Fewer generic manufacturers could lead to shortages of the life-saving medications patients rely on. A new analysis from Bates-White concludes that the Medicaid Generics Penalty “will have the unanticipated and unintended consequence of increasing the likelihood of shortages for generic medicines.”

Read More

 

What can we do about it?

Contact your representative and tell him or her to repeal the Medicaid Generics Penalty. It hurts Medicaid participants — the most vulnerable among us — and impeding access to affordable medicines for all patients.

Take Action

PDFSep 18, 2017Erica Klinger
Bates White Report - CPI-based Medicaid Generics Penalty
Download |
PDFOct 26, 2017Erica Klinger
AAM Issue Brief: Medicaid Generics Penalty
Download |
Press Release Sep 19, 2017 Rachel Schwartz
CPI Penalty on Medicaid Generic Drugs Threatens Patient Access to Affordable Medicine

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.